Sojan Joseph

This is an incredibly important and timely debate. The latest UK Health Security Agency data, published on Tuesday, underlined how vaccine rates have continued to decline. It also showed that uptake of the meningitis B booster for children aged two fell slightly last year. I find that especially alarming, given the meningitis outbreak in Kent earlier this year. There were 21 confirmed cases, tragically including the deaths of two young people. A number of schools across east Kent also recorded confirmed cases, including one in my constituency. I am grateful for the co-ordinated action led by the various agencies. Their swift response helped to ensure that clear public health advice was communicated and that vaccination programmes could be rapidly rolled out. Although I warmly welcome that action, at the time of the outbreak I joined colleagues from across the House in calling for more to be done. I was therefore pleased that, during the summer, the UKHSA and NHS England introduced a one-off national meningitis B vaccination programme to protect young people at the highest risk before the start of the new academic year, when meningitis B cases typically rise. The Joint Committee on Vaccination and Immunisation also published a number of recommendations on a routine meningitis B programme for adolescents. Before the summer recess, the Government were considering those recommendations. Will the Minister provide an update on those considerations? The meningitis outbreak in Kent should serve as a warning of the serious consequences when vaccine-preventable diseases regain ground. As the chair of the all-party parliamentary group for global tuberculosis, I also point to rising rates of TB in the UK. TB meningitis is one of the most severe forms of TB, particularly in young children. The BCG vaccine protects against TB, particularly serious forms of the infection such as TB meningitis. However, the latest data for the UK shows that, in the first quarter of the year, almost one in five children eligible for the BCG vaccine did not receive it. Vaccinations remain an important part of preventing severe childhood TB, alongside early diagnosis and treatment. However, the BCG vaccine is more than 100 years old and does not provide reliable protection against pulmonary TB in adults. I therefore stress the need for continued investment in research and development on new, more effective TB vaccines. That is particularly important, given the country’s role in global tuberculosis research and development. My hon. Friend the Member for Bury St Edmunds and Stowmarket (Dr Prinsley) talked about Reform using its conference stage to talk about an anti-vaccination programme. We have a duty to base our discussions about vaccinations on facts and evidence. As politicians, we have a particular responsibility to promote clear, evidence-based information and to avoid contributing to uncertainty and mistrust.